Compare YieldMax AMD Option Income Strategy ETF (AMDY) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMD Option Income Strategy ETF vs Amphastar Pharmaceuticals Inc — how do they compare? YieldMax AMD Option Income Strategy ETF trades at $45.1, while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMDY | AMPH | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $59.52 | $30.81 |
52-Week Low | $29.80 | $16.87 |
Market Cap | — | $863.95M |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMDY trades at $45.61, down 0.93% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF has delivered high weekly distributions, with recent dividends ranging from $0.63 to $1.17, but faces concerns over net asset value erosion. Support is seen at $45, with resistance at $47.
The outlook is cautious due to structural NAV erosion risks highlighted by analysts. Investment opportunity lies in high income generation if AMD exhibits gradual volatility, but direct AMD exposure may be preferable for AI-driven upside. Key risks include yield sustainability and dependency on AMD's stock performance.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
